InGeneron Reports Positive Top-Line Data From its Clinical Lead Program in Rotator Cuff Tendinopathy
Feasibility study meets primary endpoints and paves the way for a pivotal study in 2019
Houston, TX, USA, December 12, 2018 – InGeneron, Inc., a regenerative medicine and cell therapy company, announced today the successful conclusion of its U.S. Food and Drug Administration (FDA)-approved feasibility study for partial rotator cuff tears. Analysis of patient data one year after treatment indicates the company’s autologous point-of-care cell therapy is safe and well-tolerated. A partial rotator cuff tear is a degenerative and often chronic indication found in the shoulder. It is one of the most common orthopedic impairments of a person’s upper extremities and is estimated to affect more than one million patients in developed economies annually.
“In addition to the study’s successful demonstration of safety, patients who received InGeneron’s regenerative cell treatment reported a reduction in pain and improvement in function,” said Glenn Winnier, PhD, Chief Scientific Officer of InGeneron. “This is very encouraging because it represents a first signal for clinical efficacy of the therapy with our platform.”
InGeneron’s FDA-approved feasibility study investigated the safety and efficacy of using adipose (fat)-derived regenerative cells to treat partial thickness rotator cuff tears involving a partial tear in the supraspinatus tendon. The cells were isolated from the patient’s own adipose tissue and processed with InGeneron’s proprietary technology at the bedside. InGeneron conducted the trial in collaboration with its clinical partner Sanford Health and enrolled a total of 18 patients ranging in age from 40 to 73 years. The allocation of treatment was randomized and single-blinded, with two-thirds of the patients receiving the adipose-derived regenerative cell injections and one-third receiving a cortisone injection as a control group. Follow-up took place at twelve months post treatment and included MRI (magnetic resonance imaging) of the patient’s shoulder. The results are being prepared for peer-reviewed publication.
“Increasingly, individuals who endure unmet medical needs in orthopedic conditions feel that they can only resort to conventional pain medication or costly surgeries,” said Angelo Moesslang, PhD, Chief Executive Officer of InGeneron. “The results of our rotator cuff tendinopathy feasibility trial provide hope that the therapy may offer a new treatment option for patients. This is encouraging as we will proceed with a pivotal study, which will be among the largest regenerative cell therapy trials in this indication to date.”
Following the positive outcome of this feasibility trial, InGeneron will continue its clinical program in rotator cuff tendinopathy with a double-blinded, multi-center pivotal study aiming to recruit more than 200 patients. The company anticipates enrolling the first patients in 2019. More information about the study is provided on ClinicalTrials.gov.
InGeneron is a clinical stage cell therapy company enabling novel, safe and evidence-based regenerative medicine therapies. Our purpose is to set new therapeutic standards by developing treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day application. We focus on helping patients who are impacted by musculoskeletal indications. www.ingeneron.com
Angelo Moesslang, PhD
Chief Executive Officer
+1 713 440 9900